{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=high+dose+FDC&page=2", "query": { "intervention": "high dose FDC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=high+dose+FDC&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T08:33:41.470Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03531905", "title": "Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2", "Cholesterolemia" ], "interventions": [ { "name": "Bempedoic acid + Ezetimibe FDC Oral Tablet", "type": "DRUG" }, { "name": "Ezetimibe 10 mg Oral Tablet", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" }, { "name": "Placebo oral capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Esperion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 242, "start_date": "2018-05-09", "completion_date": "2019-06-18", "has_results": true, "last_update_posted_date": "2020-04-09", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 4, "location_summary": "Lincoln, California • Miami, Florida • Louisville, Kentucky + 1 more", "locations": [ { "city": "Lincoln", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Suffolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03531905" }, { "nct_id": "NCT04857892", "title": "A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" }, { "name": "GSK3640254/DTG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 41, "start_date": "2021-04-21", "completion_date": "2021-09-10", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04857892" }, { "nct_id": "NCT02509104", "title": "Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Hyperplasia" ], "interventions": [ { "name": "FDC capsule of dutasteride and tamsulosin", "type": "DRUG" }, { "name": "Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 56, "start_date": "2015-07-30", "completion_date": "2015-10-10", "has_results": false, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02509104" }, { "nct_id": "NCT06719570", "title": "A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "MK-8591A", "type": "DRUG" }, { "name": "Islatravir", "type": "DRUG" }, { "name": "Doravine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2024-01-23", "completion_date": "2024-03-15", "has_results": false, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06719570" }, { "nct_id": "NCT01533935", "title": "Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "tiotropium + Olodaterol", "type": "DRUG" }, { "name": "Tiotropium", "type": "DRUG" }, { "name": "Olodaterol", "type": "DRUG" }, { "name": "Respimat", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 291, "start_date": "2012-02", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-09-15", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Austell", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533935" }, { "nct_id": "NCT01422876", "title": "Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "high dose FDC", "type": "DRUG" }, { "name": "BI 10773 high dose", "type": "DRUG" }, { "name": "high dose FDC placebo", "type": "DRUG" }, { "name": "low dose FDC placebo", "type": "DRUG" }, { "name": "high dose BI 10773 placebo", "type": "DRUG" }, { "name": "low dose FDC", "type": "DRUG" }, { "name": "BI 10773 low dose", "type": "DRUG" }, { "name": "linagliptin", "type": "DRUG" }, { "name": "linagliptin placebo", "type": "DRUG" }, { "name": "BI 10773 low dose placebo", "type": "DRUG" }, { "name": "low dose BI 10773 placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1405, "start_date": "2011-08", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-04-02", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 112, "location_summary": "Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Foley", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01422876" }, { "nct_id": "NCT00537043", "title": "A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "SK&F-105517 (COREG CR FDC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2007-10", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2010-10-19", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 2, "location_summary": "Hackensack, New Jersey • Austin, Texas", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00537043" }, { "nct_id": "NCT04093570", "title": "A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "ASTX727", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2019-09-30", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 21, "location_summary": "Fountain Valley, California • Plantation, Florida • Chicago, Illinois + 14 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04093570" }, { "nct_id": "NCT07404137", "title": "A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Zibotentan/Dapagliflozin FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 26, "start_date": "2026-02-16", "completion_date": "2026-04-02", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07404137" }, { "nct_id": "NCT05835011", "title": "A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Decitabine/Cedazuridine", "type": "DRUG" }, { "name": "Magrolimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-06-27", "completion_date": "2023-08-21", "has_results": true, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-09-23T08:33:41.470Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Plantation, Florida • Minneapolis, Minnesota", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Plantation", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05835011" } ] }